Compare CBAN & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAN | CMPX |
|---|---|---|
| Founded | 1975 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.6M | 408.8M |
| IPO Year | 1995 | 2020 |
| Metric | CBAN | CMPX |
|---|---|---|
| Price | $21.46 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 162.7K | ★ 3.4M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 16.91 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.41 | N/A |
| Revenue Next Year | $4.84 | $934.41 |
| P/E Ratio | $23.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.80 | $1.61 |
| 52 Week High | $22.46 | $6.88 |
| Indicator | CBAN | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 46.08 | 61.44 |
| Support Level | $19.20 | $1.68 |
| Resistance Level | $22.43 | $2.47 |
| Average True Range (ATR) | 0.43 | 0.14 |
| MACD | -0.14 | 0.03 |
| Stochastic Oscillator | 52.80 | 83.58 |
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.